Sales, Marketing Jobs Could Be First to Go at MedImmune (Jobs)
When MedImmune was beginning to hear shareholder grumblings to sell the company, AstraZeneca was listening to a different list of demands from its own shareholders. They wanted the British pharmaceutical giant to buy more companies and strengthen its store of drugs.
With AstraZeneca's offer to buy MedImmune for $15.2 billion -- one of the decade's biggest biotech deals -- the two companies have done their investors' bidding.